A Phase 2/3 Study of ALX148 in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 26 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evorpacept (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms ASPEN-06
Sponsors ALX Oncology

08 Aug 2024 According to a ALX Oncology media release, updated results of ASPEN-06 Phase 2 clinical trial are expected in 1H 2025.
08 Aug 2024 According to a ALX Oncology media release, Phase 2 clinical trial readout in patients with previously treated HER2-positive advanced gastric cancer is a significant growth milestone for the Company.
31 Jul 2024 Primary endpoint has been met (Phase 2: Percentage of patients with objective response per RECIST 1.1) , according to a ALX Oncology media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com